cAMP-specific 3′,5′-cyclic phosphodiesterase 4 (PDE4)

cAMP-specific 3′,5′-cyclic phosphodiesterase 4 (PDE4) is a family of enzymes crucial for cellular control of cyclic adenosine monophosphate (cAMP) levels. It specifically hydrolyzes cAMP, terminating its signaling and thereby regulating cell responses to extracellular signals like hormones and neurotransmitters. PDE4 comprises four major subtypes (PDE4A-D), with distinct tissue distributions and splice variants, and plays central roles in inflammatory and immune response modulation, neuronal signaling, mood regulation, and cognitive processes. The PDE4 enzyme family is a validated therapeutic target for several diseases, with multiple approved drugs acting as inhibitors to raise cAMP, thus exerting anti-inflammatory and psychoactive effects. However, meaningful therapeutic use is limited by side effects, particularly nausea and emesis related to CNS exposure. Selective targeting of subtypes, isoforms, or allosteric sites—alongside careful patient selection—remains an active area of drug development.

Other names

Phosphodiesterase 4cAMP-specific phosphodiesterase 4PDE4A, PDE4B, PDE4C, PDE4D (refers to subtypes)EC 3.1.4.53 (Enzyme Commission number)3',5'-cyclic-AMP phosphodiesterase 4DPDE3, PDE43

Competitive or allosteric inhibition of PDE4, increasing cellular cAMP concentrations, which in turn activates PKA and downstream anti-inflammatory, neuroprotective, and mood-regulating effects. Allosteric modulators may target specific isoforms or regulatory domains (UCR1/UCR2) for enhanced specificity or reduced side effects